BT and Accelrys Technologies Unlock Value in Big Data - Pharmaceutical Technology

Latest Issue
PharmTech

Latest Issue
PharmTech Europe

BT and Accelrys Technologies Unlock Value in Big Data


British Telecommunications (BT) and Accelrys are collaborating to provide solutions for analyzing massive datasets using BT for Life Sciences Cloud Compute Platform combined with Accelrys Enterprise Platform and Accelrys Pipeline Pilot software, the companies announced in a press release.  The tools can be used to mine information on healthcare topics from very large datasets.

BT has collated publically available health system and social care information into a research repository intended for use by the life sciences and healthcare industries as well as academia, initially hosted in the United States and United Kingdom, but available for global access. Such data can provide valuable insight into a number of healthcare topics, such as disease prevalence, impact of ethnic mix and adverse drug reactions. However, the information is often contained in very large datasets and may be unstructured in nature. The datasets can be analyzed using the BT and Accelrys tools.

“The generation of ever-increasing amounts of health data is both a blessing and a curse, as they are data-rich, but often information-poor,” said Leif Pedersen, senior vice president of marketing, product management and corporate development at Accelrys, in the press release. “Working with BT, we’ve shown that we can deliver meaningful and valuable insights from these huge datasets.”

ADVERTISEMENT

blog comments powered by Disqus
LCGC E-mail Newsletters

Subscribe: Click to learn more about the newsletter
| Weekly
| Monthly
|Monthly
| Weekly

Survey
Which of the following business challenge poses the greatest threat to your company?
Building a sustainable pipeline of products
Attracting a skilled workforce
Obtaining/maintaining adequate financing
Regulatory compliance
Building a sustainable pipeline of products
30%
Attracting a skilled workforce
27%
Obtaining/maintaining adequate financing
14%
Regulatory compliance
30%
View Results
Eric Langer Outsourcing Outlook Eric LangerBiopharma Outsourcing Activities Update
Cynthia Challener, PhD Ingredients Insider Cynthia Challener, PhDAppropriate Process Design Critical for Commercial Manufacture of Highly Potent APIs
Jill Wechsler Regulatory Watch Jill Wechsler FDA and Manufacturers Seek a More Secure Drug Supply Chain
Sean Milmo European Regulatory WatcchSean MilmoQuality by Design?Bridging the Gap between Concept and Implementation
Medicare Payment Data Raises Questions About Drug Costs
FDA Wants You!
A New Strategy to Tackle Antibiotic Resistance
Drug-Diagnostic Development Stymied by Payer Concerns
Obama Administration Halts Attack on Medicare Drug Plans

Click here